Ah Kioon MD, Tripodo C, Fernandez D, et al. Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8. Sci Transl Med. 2018;10:eaam8458.
Amitay-Laish I, Sundram U, Hoppe RT, et al. Localized skin-limited blastic plasmacytoid dendritic cell neoplasm: A subset with possible durable remission without transplantation. JAAD Case Rep. 2017;3(4):310-315.
Arber DA, Orazi A, Hasserjian R, Thiele J, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405.
Bastidas Torres AN, Cats D, Mei H, et al. Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm. Genes Chromosomes Cancer. 2020;59:295-308.
Bôle-Richard E, Fredon M, Biichlé S, et al. CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2020;34:3228-3241.
Brody JP, Allen S, Schulman P, et al. Acute agranular CD4-positive natural killer cell leukemia. Comprehensive clinicopathologic studies including virologic and in vitro culture with inducing agents. Cancer. 1995;75:2474-2483.
Chan JKC, et al. NK-cell lymphoma. In: World Health Organization classification of tumors. Lyon, France: IARC Press;2001:214-215.
ClinicalTrials.gov. Study of venetoclax, a BCL2 antagonist, for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Updated October 20, 2020. Accessed November 1, 2020. https://clinicaltrials.gov/ct2/show/NCT03485547
ClinicalTrials.gov. Combination chemotherapy in patients with newly diagnosed BPDCN (LpDessai). Updated March 18, 2019. Accessed November 1, 2020. https://clinicaltrials.gov/ct2/show/NCT03599960
ClinicalTrials.gov. Flotetuzumab in treating patients with recurrent or refractory CD123 positive blood cancer. Updated February 10, 2020. Accessed November 1, 2020. https://clinicaltrials.gov/ct2/show/NCT03739606
Cota C, Vale E, Viana I, et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol. 2010;34(1):75‐87.
Daver NG, Montesinos P, DeAngelo DJ, et al. Clinical profile of IMGN632, a novel CD123-targeting antibody-drug conjugate (ADC), in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood. 2019;134(Suppl_1): Abstract 734.
Facchetti F, et al. Blastic plasmacytoid dendritic cell neoplasm. In: WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008:145-147.
Facchetti F, Cigognetti M, Fisogni S, et al. Neoplasms derived from plasmacytoid dendritic cells. Modern Pathol. 2016;29:98-111.
Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124:385-392.
Griffin GK, Togami K, Morgan EA, et al. Developmental ontogeny of blastic plasmacytoid dendritic cell neoplasm (BPDCN) revealed by recurrent high burden clonal hematopoiesis, including in "skin-only" disease. Blood 2018;132(Suppl_1): Abstract 2755.
Garnache-Ottou F, Vidal C, Biichlé S,et al. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? Blood Adv. 2019;3:4238-4251.
Julia F, Petrella T, Beylot-Barry M, et al. Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol. 2012;169:579-586.
Manz MG. Plasmacytoid dendritic cells: origin matters. Nat Immunol. 2018;19:652-654.
Martín-Martín L, Almeida J, Pomares H, et al. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget. 2016;7:10174-10181.
Montero J, Stephansky J, Cai T, et al. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is highly BCL-2 dependent and sensitive to venetoclax. Blood. 2016;128: Abstract 4045.
Montero J, Stephansky J, Cai T, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer Discov. 2017;7:156-164.
National Comprehensive Cancer Network (NCCN). Acute myeloid leukemia. (Version 3.2020). Published December 23, 2019. Accessed October 1, 2020. http://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
Pagano L, Valentini CG, Grammatico S, et al. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174:188-202.
Pagano L, Valentini CG, Pulsoni A, et al; GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell'Adulto, Acute Leukemia Working Party). Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98:239-246.
Pemmaraju N, ane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380:1628-1637.
Riaz W, Zhang L, Horna P, et al. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. Cancer Control. 2014;21:279-289
Saadeh D, et al. Kurban M, Abbas O. Update on the role of plasmacytoid dendritic cells in inflammatory/autoimmune skin diseases. Exp Dermatol. 2016;25:415-442.
Sapienza MR, Pileri A, Derenzini E, et al. Blastic plasmacytoid dendritic cell neoplasm: state of the art and prospects. Cancers (Basel). 2019;11:595.
Subtil, A. Myeloid neoplasms. Clin Lab Med. 2017;37:575-585.
Sullivan JM, Rizzieri DA. Treatment of blastic plasmacytoid dendritic cell neoplasm. Hematology Am Soc Hematol Educ Program. 2016;2016:16-23.
Sweet K. Blastic plasmacytoid dendritic cell neoplasm: diagnosis, manifestations, and treatment. Curr Opin Hematol. 2020;27:103-107.
Takagi H, Arimura K, Uto T, et al. Plasmacytoid dendritic cells orchestrate TLR7-mediated innate and adaptive immunity for the initiation of autoimmune inflammation. Sci Rep. 2016;6:24477.
Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomarker Res. 2014;2:4.
Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768-3785.

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Brian Poligone, MD, PhD

Medical Director
Rochester Skin Lymphoma Medical Group
Fairport, New York

Disclosures

Disclosure: Brian Poligone, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Helsinn Therapeutics; Kyowa Hakko Kirin; Stemline Therapeutics
Served as a speaker or a member of a speakers bureau for: Regeneron; Stemline Therapeutics; Therakos
Received grants for clinical research from: Bioniz; Helsinn Therapeutics; Mirage; Soligenix

Editor

Mindy Tanzola, PhD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Mindy Tanzola, PhD, has disclosed no relevant financial relationships.

CME Reviewer

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

CME / ABIM MOC

Case Studies in Blastic Plasmacytoid Dendritic Cell Neoplasm: Tackling the Diagnostic Challenge

Authors: Brian Poligone, MD, PhD
CME / ABIM MOC Released: 12/10/2020
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 12/10/2021

Start Activity

Target Audience and Goal Statement

This activity is intended for dermatologists, pathologists, dermato-pathologists, dermato-oncologists, and hematologists/oncologists.

The goal of this activity is to improve physician knowledge of blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to improve competence diagnosing this rare malignancy based on pathology and clinical presentation.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Typical clinical presentation of BPDCN
- Most common surface antigens expressed in BPDCN
Have greater competence related to
- Ordering appropriate tests to diagnose BPDCN
- Identifying common pathologic findings of BPDCN

Disclosures

Faculty

Brian Poligone, MD, PhD

Medical Director
Rochester Skin Lymphoma Medical Group
Fairport, New York

Disclosures

Disclosure: Brian Poligone, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Helsinn Therapeutics; Kyowa Hakko Kirin; Stemline Therapeutics
Served as a speaker or a member of a speakers bureau for: Regeneron; Stemline Therapeutics; Therakos
Received grants for clinical research from: Bioniz; Helsinn Therapeutics; Mirage; Soligenix

Editor

Mindy Tanzola, PhD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Mindy Tanzola, PhD, has disclosed no relevant financial relationships.

CME Reviewer

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC

Case Studies in Blastic Plasmacytoid Dendritic Cell Neoplasm: Tackling the Diagnostic Challenge

Authors: Brian Poligone, MD, PhDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC Released: 12/10/2020

Valid for credit through: 12/10/2021

processing....

Educational Impact Challenge

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 4

CME / ABIM MOC Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Brian Poligone, MD, PhD

Editor

Mindy Tanzola, PhD

CME Reviewer

Stephanie Corder, ND, RN, CHCP

CME / ABIM MOC

Case Studies in Blastic Plasmacytoid Dendritic Cell Neoplasm: Tackling the Diagnostic Challenge

Target Audience and Goal Statement

Disclosures

Faculty

Brian Poligone, MD, PhD

Editor

Mindy Tanzola, PhD

CME Reviewer

Stephanie Corder, ND, RN, CHCP

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Case Studies in Blastic Plasmacytoid Dendritic Cell Neoplasm: Tackling the Diagnostic Challenge

Educational Impact Challenge